ZyVersa Therapeutics, Inc.
ZVSA · OTCMCIK 1859007fmd_1JXYPAFQTDQE9NHASCQC8NVS2XManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Mar 31, 2026, 20 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Net interest income | 0 | (0) | (1) |
| Research and development | 3 | 2 | 1 |
| Total operating expenses | 108 | 9 | 25 |
| Operating income | (108) | (9) | (25) |
| Income before taxes | (108) | (9) | (26) |
| Income tax expense | (9) | 0 | (1) |
| Net income from continuing operations | (98) | (9) | (25) |
| Net income | (98) | (9) | (25) |
| Net income to common shareholders | (106) | (9) | – |